title: Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
abstract: Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies resulted in both transient nonresponsiveness of TILs to IL-2 and transient decrease in the number of live tumour cells in most melanoma patients.
authors.affiliation: Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: K
authors.initials: K
authors.lastname: Itoh
authors.forename: C M
authors.initials: CM
authors.lastname: Balch
authors.forename: J L
authors.initials: JL
authors.lastname: Murray
authors.forename: D R
authors.initials: DR
authors.lastname: Parkinson
authors.forename: A B
authors.initials: AB
authors.lastname: Markowitz
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: A A
authors.initials: AA
authors.lastname: Zukiwski
authors.forename: M I
authors.initials: MI
authors.lastname: Ross
authors.forename: S S
authors.initials: SS
authors.lastname: Legha
mesh_terms: D002452:Cell Count; D002478:Cells, Cultured; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D013997:Time Factors
chemical_list: D007376:Interleukin-2